Fulzerasib yoyamba (1L) + cetuximab mu KRAS G12Cm advanced NSCLC: kusinthidwa kwa magwiridwe antchito ndi chitetezo kuchokera ku kafukufuku wa KROCUS

Posachedwapa, GenFleet yalengeza za kafukufuku wa KROCUS, fulzerasib (GFH925, KRAS G12C inhibitor) pamodzi ndi cetuximab pochiza khansa ya m'mapapo yopanda maselo ang'onoang'ono (NSCLC), mu chidule chomwe chinaperekedwa pa msonkhano wapachaka wa European Lung Cancer Conference (ELCC) wa 2025.

Fulzerasib ndi mankhwala oyamba oletsa khansa a KRAS G12C opangidwa ku China omwe avomerezedwa ndi kuperekedwa ndi Priority Review Designation ndi NMPA. Fulzerasib idalandiranso Breakthrough Therapy Designations chaka chino pochiza odwala a KRAS G12C-mutant NSCLC omwe adalandira chithandizo chimodzi chamankhwala ndi odwala a CRC omwe adalandira chithandizo chamankhwala ... GFH925 ndi mankhwala atsopano, ogwiritsidwa ntchito pakamwa, komanso amphamvu a KRAS G12C opangidwa kuti azitha kukhudza kusinthana kwa GTP/GDP, gawo lofunikira kwambiri pakuyambitsa njira, mwa kusintha zotsalira za cysteine ​​​​za puloteni ya KRAS G12C molumikizana komanso mosasinthika. Kafukufuku wokhudza kusankha kwa cysteine ​​​​asanachitike adawonetsa kusankha kwakukulu kwa fulzerasib kupita ku G12C. Pambuyo pake, fulzerasib imaletsa bwino njira yotsika ya chizindikiro kuti ipangitse maselo a chotupa kufalikira komanso kuletsa kuzungulira kwa maselo.

Odwala 47 omwe sanalandire chithandizo cha KRAS G12C-mutant NSCLC omwe sanalandire chithandizo adathandizidwa ndi fulzerasib pamodzi ndi cetuximab (fulzerasib 600mg BID + cetuximab 500 mg/m2 Q2W) kuyambira pa Januware 14, 2025.

Kugwira Ntchito: Pofika tsiku lomaliza la deta, pakati pa odwala 45 omwe adalandira kafukufuku kamodzi kokha atalandira chithandizo cha khansa, ORR inali 80% ndipo DCR inali 100%; 57.8% anali ndi ≥ 50% ya chotupa. Odwala 16 (34%) anali ndi metastasis muubongo; pakati pa odwala 14 omwe adalandira kafukufuku kamodzi kokha atalandira chithandizo cha khansa, ORR pa RECIST 1.1 inali 71.4%. Nthawi yapakati yoyankhira (DoR) sinafike, ndipo odwala 24 anali akadali pa chithandizo ndi kutsatiridwa kwapakati kwa miyezi 10.1. MPFS inali miyezi 12.5 ndipo mOS sinafike.

Chitetezo: Pofika tsiku lomaliza la deta, mankhwala ophatikizana adapereka mbiri yabwino yachitetezo/kulekerera. TRAEs idachitika mwa odwala 87.2% ndipo ambiri mwa odwala a TRAE adapatsidwa giredi 1-2; 14.9% ya odwala adakumana ndi TRAEs imodzi ya giredi 3; palibe TRAEs ya giredi 4-5. Odwala awiri adakumana ndi zochitika zoyipa zokhudzana ndi chithandizo (TRSAE) ndipo TRSAEs adayesedwa kuti anali okhudzana ndi cetuximab; Odwala atatu adakumana ndi TRAEs, zosagwirizana ndi fulzerasib, zomwe zidapangitsa kuti mlingo usiye. KROCUS idawonetsa kuchepa kwa kuchepa kwa mlingo kapena kuchepa pakati pa maphunziro osiyanasiyana oyamba a G12C-mutant NSLCL. Palibe zizindikiro zatsopano zachitetezo zomwe zidapezeka poyerekeza ndi fulzerasib kapena cetuximab ngati mankhwala amodzi.

Pakadali pano, pali mayesero ambiri azachipatala a ukadaulo watsopano wothana ndi khansa ku China omwe akufuna odwala. Mukafunsira mankhwala ndi ukadaulo watsopano, mutha kulumikizana ndi Dipatimenti Yapadziko Lonse ya Chipatala cha Oncology ku Beijing South Region.

Nambala ya Foni: 4008803716

Email：myimmnet@163.com